首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1424295

全球血漿蛋白治療市場：按產品類型、按應用、按最終用戶、按地區

Global Plasma Protein Therapeutic Market, By Product Type, By Application (Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Others), By End User, By Geography

出版日期: 2023年12月26日 | 出版商:

Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球血漿蛋白治療市場規模預計將從 2023 年的 299.7 億美元增至 2030 年的 464.9 億美元，預測期內複合年成長率為 6.5%。

報告範圍		報告詳情
基準年	2022年	2023/2024年市場規模	299.7億美元
實際資料	2018-2021	預測期	2023-2030
預測期間 2023/2024 至 2030/2031 年複合年成長率：	6.50%	2030/2031 年預計金額	464.9億美元

圖 1. 2023 年血漿蛋白治療的全球市場佔有率(%)（按地區）

血漿蛋白療法是指從人類血漿中提取的治療產品，用於治療多種疾病，包括慢性疾病。血漿含有 700 多種蛋白質，它們在體內發揮多種重要功能。主要血漿蛋白治療劑包括免疫球蛋白、凝血因子、白蛋白和其他特殊蛋白質。這些血漿衍生產品有助於增強免疫系統、凝血和其他代謝過程。隨著患有慢性疾病的老化人口的增加，全世界對血漿療法的需求正在增加。此外，先進的精製技術使得以經濟高效的方式從血漿中回收大量重要蛋白質成為可能。

市場動態：.

全球血漿蛋白治療市場是由需要血漿替代治療的免疫不全症和遺傳患者病率上升所推動的。人口老化也支持了需求，人口老化更容易患出血性疾病等慢性病。持續研發新的血漿衍生產品並擴大健康保險系統的覆蓋範圍正在該領域創造商機。然而，有關血漿收集的嚴格規定以及血漿分餾工廠所需的高資本是挑戰。此外，替代基因改造療法的出現也威脅著市場的成長。在缺乏適當篩檢的情況下購買血漿的安全問題也阻礙了市場的成長。

例如，根據國家生物技術資訊中心2023年6月26日發布的報告，2021年韓國原發性免疫力缺乏（PID）發生率約為每百萬兒童11.25例。最常見的免疫力缺乏是抗體相關的，佔53.3%，其次是吞噬細胞障礙，佔28.9%。

本研究的主要特點

該報告對全球血漿蛋白治療市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
它還強調了各個細分市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球血漿蛋白治療市場的主要企業。
該報告的見解使行銷人員和經營團隊負責人就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球血漿蛋白治療市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球血漿蛋白治療市場的各種策略矩陣來促進他們的決策。

北美洲
美國
加拿大
歐洲
德國
英國
西班牙
法國
義大利
俄羅斯
其他歐洲國家
亞太地區
中國
印度
日本
澳洲
韓國
ASEAN
其他亞太地區
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
中東
海灣合作理事會國家
以色列
其他中東地區
非洲
北非
中部非洲
南非

第9章競爭形勢

Octapharma USA Inc.
Biotest AG
Kedrion SpA
CSL Limited
Grifols, SA
Takeda Pharmaceutical Company Limited.
Octapharma AG
Bio Products Laboratory（BPL）
Shire Plc
Albumedix Ltd.

第10章

調查方法
關於出版商

簡介目錄

Product Code: CMI6511

The Global Plasma Protein Therapeutic Market size is expected to reach US$ 46.49 Bn by 2030, from US$ 29.97 Bn in 2023, exhibiting a CAGR of 6.5% during the forecast period.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023/2024:	US$ 29.97 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR:	6.50%	2030/2031 Value Projection:	US$ 46.49 Bn

Figure 1. Global Plasma Protein Therapeutic Market Share (%), By Region, 2023

Global Plasma Protein Therapeutic Market - IMG1

Plasma protein therapeutic refers to therapeutic products that are derived from human blood plasma and are used for treating various medical conditions such as chronic disease and others. Blood plasma contains over 700 different proteins and serves various important functions in the body. Some of the major plasma protein therapeutics include immunoglobulins, coagulation factors, albumin, and other specialty proteins. These plasma derived products help in boosting the immune system, blood clotting, and other metabolic processes. With the growing geriatric population suffering from chronic diseases, there has been a rise in the demand for plasma therapeutics globally. Also, advanced purification technology has enabled significant yield of critical proteins from plasma in a cost-effective manner.

Market Dynamics:

The global plasma protein therapeutic market is driven by the rising prevalence of immune deficiency diseases and genetic disorders requiring plasma replacement therapies. The growing geriatric population prone to chronic illnesses like bleeding disorders is also supporting the demand. Continuous R&D efforts to develop new plasma-derived products and wider coverage under medical insurance schemes are providing opportunities in this space. However, stringent regulations pertaining to plasma collection and high capital requirements for plasma fractionation plants act as challenges. Also, the emergence of alternative recombinant therapies threatens the market growth. Safety concerns around plasma sourcing if not properly screened also hinder the market growth.

For instance, on June 26, 2023, according to a report published by the National Center for Biotechnology Information, in 2021, in South Korea, the occurrence rate of primary immunodeficiencies (PID) stood at around 11.25 cases per million children. The most commonly identified immunodeficiencies were those related to antibodies, constituting 53.3%, with phagocytic disorders trailing at 28.9%.

Key features of the study:

This report provides an in-depth analysis of the global plasma protein therapeutic market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasma protein therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Octapharma USA Inc., Biotest AG, Kedrion S.p.A, CSL Limited, Grifols, S.A, Takeda Pharmaceutical Company Limited., Octapharma AG, Bio Products Laboratory (BPL), Shire Plc, and Albumedix Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global plasma protein therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protein therapeutic market

Global Plasma Protein Therapeutic Market Detailed Segmentation:

By Product Type
- Albumin
- Immunoglobulin
- Plasma-derived Factor VIII
- Others
By Application
- Haemophilia
- Primary Immunodeficiency Disorder (PIDD)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others
By End User
- Hospitals
- Clinics
- Research Laboratories
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Top Companies in the Global Plasma Protein Therapeutic Market:
- Octapharma USA Inc.
- Biotest AG
- Kedrion S.p.A
- CSL Limited
- Grifols, S.A
- Takeda Pharmaceutical Company Limited.
- Octapharma AG
- Bio Products Laboratory (BPL)
- Shire Plc
- Albumedix Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Plasma Protein Therapeutic Market, By Product Type
- Global Plasma Protein Therapeutic Market, By Application
- Global Plasma Protein Therapeutic Market, By End User
- Global Plasma Protein Therapeutic Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing Prevalence of Complement Deficiency Diseases
- High R&D and Production Costs
- Immune Globulin for Various Disease Treatment
Impact Analysis
Key Highlights
Regulatory Scenario
Service offering Portfolio
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Plasma Protein Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Plasma Protein Therapeutic Market, By Product Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Albumin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Plasma-derived Factor VIII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Plasma Protein Therapeutic Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Haemophilia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Primary Immunodeficiency Disorder (PIDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Idiopathic Thrombocytopenic Purpura (ITP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Plasma Protein Therapeutic Market, By End User, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Research Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Plasma Protein Therapeutic Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country, 2019 - 2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030,(US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Octapharma USA Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Biotest AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Kedrion S.p.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Grifols, S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bio Products Laboratory (BPL)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Shire Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Albumedix Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views